Table 3.
Treatment regimens and detected metastasis during follow-up.
| Characteristics | Study Groups | ||
|---|---|---|---|
| CE-CT (286 scan) | FDG-PET/CT (189 scan) | ||
| Received treatments during follow-up a | Endocrine therapy | 29 (85.3) | 25 (80.6) |
| Bone-targeted therapies | 24 (70.6) | 23 (74.2) | |
| Chemotherapy | 22 (64.7) | 18 (58.1) | |
| CDK4/6 inhibitors | 19 (55.9) | 15 (48.4) | |
| Anti-HER2 therapy | 5 (14.7) | 6 (19.4) | |
| Palliative radiotherapy | 5 (14.7) | 1 (3.2) | |
| Metastatic sites during follow-up b | Bone | 166 (58.0) | 90 (47.6) |
| Liver | 55 (19.2) | 15 (7.9) | |
| Lung/plural | 110 (38.5) | 66 (34.9) | |
| Regional/distant lymph nodes | 112 (39.2) | 67 (35.4) | |
| Others c | 48 (16.8) | 28 (14.8) | |
CE-CT: contrast-enhanced computed tomography, FDG-PET/CT: fluorodeoxyglucose positron emission tomography with integrated computed-tomography. a Data shown as frequency (percentage) out of patients’ number. b Data shown as frequency (percentage) out of number of scans. c Others comprised ascites, adrenal glands, thyroid, uterus, colon, soft tissue, and skin.